

REMARKS

Favorable consideration and allowance of the application is respectfully requested.

Claims 1-7 were in the application, claims 2-4 were amended and new claims 8-10 have been added.

The examiner indicated that the amendment to remove "pharmaceutical" as to claims 2 and 3 would overcome the rejection of these claims under 35 U.S.C. §112. However, in view of the discussion below, this request is believed to be rendered moot.

Claims 4-7 were rejected under 35 U.S.C. §112. Claim 4 has been amended to relate to GP120 mediated neuronal cell loss, to correspond with the description in the specification, page 1, line 1 through page 2 line 13, and the example, page 5, line 1 through page 7, line 19. By this amendment, it is believed claim 4 is now of sufficiently narrow scope, relating to GP120 neurotoxicity, as to overcome the rejection under 35 U.S.C. §112. By this amendment, claims 2 and 3 are additionally believed to be enabled.

The examiner's request for in vivo results is believed unwarranted. The application identified the disease for treatment and the applicable symptoms, that is, the applicant's discussed "neuro-aids", which one skilled in the art would recognize from the test discussed in the application, that in a dose dependant fashion, the peptides of the invention inhibiting neuronal loss caused by GP120, and offers various ranges for treatment of individuals, with the inventive peptides.

There certainly is no undue experimentation needed to make or use the invention. As the examiner should be aware, the synthesis of the peptides of the invention would be routine to one of ordinary skill in the art, following the description on Page 8, lines 4-7. Use of the invention would also be routine, as the sequences themselves are clearly identified, and one skilled in the art would be familiar with various delivery vehicles used to administer peptides as treatment compositions, as these have been in use for many years.

As the teaching in the specification of how to make and use the invention are co-extensive with the scope of the invention as now claimed, claims 4-7 are believed to be in proper form for allowance.


New claims 8 and 9 depend from and contain all the limitations of claim 4 therein and are equally believed to be in form for allowance.

New claim 10 is directed to treating Alzheimer's disease, and the neuropathy of Alzheimer's disease is well known, and a treatment that inhibits neuronal cell loss would be of particular value in treating the disease. As above, the scope of the claim is co-extensive with the disclosure in the application and the claim is believed properly supported. In vivo testing is certainly unnecessary and would constitute an unwarranted burden on applicants who have shown the in vivo inhibiting effects of the identified peptides, sufficient to support patentability of the invention of claim 10. Consequently, claim 10 is also believed to be allowable.

Based on the above amendments and remarks, reconsideration and allowance of the application is respectfully requested. However should the examiner believe that direct contact with the applicant's attorney would advance the prosecution of the application, the examiner is invited to telephone the undersigned at the number given below.

COLEMAN SUDOL SAPONE, P.C.
714 Colorado Avenue
Bridgeport, Connecticut 06605-1601
Telephone No. (203) 366-3560
Facsimile No. (203) 335-6779

Respectfully submitted,


William J. Sapon
Registration No. 32,518
Attorney for Applicant(s)

RECEIVED

SEP 04 2003

TECH CENTER 1600/2390

SUBSTITUTE SHEET (RULE 26)

NEURONAL
CELL COUNTS




FIG. 1

○ IKEYFTS
□ LESYT
△ IKEYF